JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA) granted Breakthrough Therapy Designation for Carteyva® (relmacabtagene autoleucel injection) as second-line treatment in adults with relapsed or refractory large B-cell lymphoma...
Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio
HANGZHOU, China, Jan. 10, 2025 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration agreement for the global development and commercialization of a portfolio of metabolic diseases therapies in territories outside of Greater China and South Korea, with Verdiva Bio Limited ("Verdiva"), a clinical-stage...
SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA
SEOUL, South Korea, Jan. 10, 2025 /PRNewswire/ -- SN BioScience today announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial. This achievement follows the designation of SNB-101 as an orphan drug for small cell lung...
TriNetX’s Founding CEO Announces Plans to Step Down
After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX's Board CAMBRIDGE, Mass., Jan. 9, 2025 /PRNewswire/ -- TriNetX, the largest global source of real-world data, today announced that Gadi Lachman, the Company's Founder, President and CEO, will step down from his operating role on March 31, 2025. Gadi founded...
In 2024, Complete Genomics expanded U.S. manufacturing and technology capabilities toward a diversified, reliable supply chain for its flexible and cost-effective NGS solutions
SAN JOSE, Calif., Jan. 10, 2025 /PRNewswire/ -- In 2024, Complete Genomics, a pioneering genomic sequencing company, expanded its U.S. manufacturing footprint with augmented technology capabilities to diversify its supply chain helping it to continue reliably serving customers with flexible, cost-effective next generation sequencing (NGS) solutions. Expanding U.S. manufacturing capabilities in 2024 and beyond After weathering a year of geopolitical...
United Imaging Announces Major Expansion of U.S. Manufacturing Space
The additional space will more than triple the square footage of the company's current production facility and headquarters in Houston, Texas HOUSTON, Jan. 10, 2025 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has signed on for additional production and office space in greater Houston. The new space in Pearland, Texas will...
Argon Medical Announces First Patient Enrollment in CLEAN-PE, a Prospective, Multicenter Study of a New Treatment for Pulmonary Embolism
PLANO, Texas, Jan. 9, 2025 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the first patient enrollment in the CLEAN-PE study. The prospective, multicenter CLEAN-PE study aims to evaluate the safety and efficacy of the Cleaner™ Pro...
Goertek Unveils Next-Generation Smart Ring Reference Designs: A Leap Forward in Health Monitoring and Interactive Technology
LAS VEGAS, Jan. 9, 2025 /PRNewswire/ -- Recent technological advancements in sensing, big data, cloud computing, IoT, and AI have significantly enhanced the capabilities of wearable devices in health monitoring. Goertek's latest smart ring reference designs, showcased at CES 2025, embodies these innovations, offering a unique combination of technology and style that aligns with modern lifestyle needs. This device stands...
Hengdian Group Capital and Apeloa Pharmaceutical to participate in 2025 J.P. Morgan Healthcare Conference
HANGZHOU, China, Jan. 9, 2025 /PRNewswire/ -- Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025. HgC CEO Gary Xu and Apeloa VP George Cai will be present along with their teams to connect with...
UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process These advancements have the potential to transform antibody discovery methods, broadening therapeutic applications and accelerating the development of innovative molecules CAMBRIDGE, Mass. and BRUSSELS, Jan. 9, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical...
